366 related articles for article (PubMed ID: 34560140)
21. Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis.
McGregor JG; Hogan SL; Kotzen ES; Poulton CJ; Hu Y; Negrete-Lopez R; Kidd JM; Katsanos SL; Bunch DO; Nachman PH; Falk RJ
Nephrol Dial Transplant; 2015 Apr; 30 Suppl 1(Suppl 1):i123-31. PubMed ID: 25805743
[TBL] [Abstract][Full Text] [Related]
22. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
Guillevin L; Pagnoux C; Karras A; Khouatra C; Aumaître O; Cohen P; Maurier F; Decaux O; Ninet J; Gobert P; Quémeneur T; Blanchard-Delaunay C; Godmer P; Puéchal X; Carron PL; Hatron PY; Limal N; Hamidou M; Ducret M; Daugas E; Papo T; Bonnotte B; Mahr A; Ravaud P; Mouthon L;
N Engl J Med; 2014 Nov; 371(19):1771-80. PubMed ID: 25372085
[TBL] [Abstract][Full Text] [Related]
23. A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis.
Pepper RJ; McAdoo SP; Moran SM; Kelly D; Scott J; Hamour S; Burns A; Griffith M; Galliford J; Levy JB; Cairns TD; Gopaluni S; Jones RB; Jayne D; Little MA; Pusey CD; Salama AD
Rheumatology (Oxford); 2019 Feb; 58(2):260-268. PubMed ID: 30239910
[TBL] [Abstract][Full Text] [Related]
24. Reduced-dose versus high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: predefined 2-year follow-up study.
Furuta S; Nakagomi D; Kobayashi Y; Hiraguri M; Sugiyama T; Amano K; Umibe T; Kono H; Kurasawa K; Kita Y; Matsumura R; Kaneko Y; Ninagawa K; Hiromura K; Kagami SI; Inaba Y; Hanaoka H; Ikeda K; Nakajima H;
Ann Rheum Dis; 2024 Jan; 83(1):96-102. PubMed ID: 37734880
[TBL] [Abstract][Full Text] [Related]
25. Novel Therapies for ANCA-associated Vasculitis.
Monti S; Brandolino F; Milanesi A; Xoxi B; Delvino P; Montecucco C
Curr Rheumatol Rep; 2021 Apr; 23(6):38. PubMed ID: 33909172
[TBL] [Abstract][Full Text] [Related]
26. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis.
Walsh M; Merkel PA; Peh CA; Szpirt WM; Puéchal X; Fujimoto S; Hawley CM; Khalidi N; Floßmann O; Wald R; Girard LP; Levin A; Gregorini G; Harper L; Clark WF; Pagnoux C; Specks U; Smyth L; Tesar V; Ito-Ihara T; de Zoysa JR; Szczeklik W; Flores-Suárez LF; Carette S; Guillevin L; Pusey CD; Casian AL; Brezina B; Mazzetti A; McAlear CA; Broadhurst E; Reidlinger D; Mehta S; Ives N; Jayne DRW;
N Engl J Med; 2020 Feb; 382(7):622-631. PubMed ID: 32053298
[TBL] [Abstract][Full Text] [Related]
27. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.
de Groot K; Harper L; Jayne DR; Flores Suarez LF; Gregorini G; Gross WL; Luqmani R; Pusey CD; Rasmussen N; Sinico RA; Tesar V; Vanhille P; Westman K; Savage CO;
Ann Intern Med; 2009 May; 150(10):670-80. PubMed ID: 19451574
[TBL] [Abstract][Full Text] [Related]
28. Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission in Nonlife-Threatening Relapses of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Randomized, Controlled Trial.
Tuin J; Stassen PM; Bogdan DI; Broekroelofs J; van Paassen P; Cohen Tervaert JW; Sanders JS; Stegeman CA
Clin J Am Soc Nephrol; 2019 Jul; 14(7):1021-1028. PubMed ID: 31253599
[TBL] [Abstract][Full Text] [Related]
29. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
Timlin H; Lee SM; Manno RL; Seo P; Geetha D
Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088
[TBL] [Abstract][Full Text] [Related]
30. Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis.
Thiel J; Troilo A; Salzer U; Schleyer T; Halmschlag K; Rizzi M; Frede N; Venhoff A; Voll RE; Venhoff N
J Allergy Clin Immunol Pract; 2017; 5(6):1556-1563. PubMed ID: 28916432
[TBL] [Abstract][Full Text] [Related]
31. Systematic review and meta-analysis for 2023 clinical practice guidelines of the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis for the management of ANCA-associated vasculitis.
Watanabe R; Oshima M; Nishioka N; Sada KE; Nagasaka K; Akiyama M; Ando T; Higuchi T; Inoue Y; Kida T; Mutoh T; Nakabayashi A; Onishi A; Sakai R; Waki D; Yamada Y; Yajima N; Tamura N; Kaname S; Harigai M
Mod Rheumatol; 2023 Aug; 33(5):982-989. PubMed ID: 36112482
[TBL] [Abstract][Full Text] [Related]
32. ANCA-associated pulmonary-renal syndrome treated with cyclophosphamide, rituximab, repeated methyl-prednisolone pulses and a reduced oral glucocorticoid regime: an observational study.
Gómez-Carballo C; Soto-Peleteiro A; Olmo-Velasco M; Bueno L; Ruiz-Arruza I; Ruiz-Irastorza G
Clin Exp Rheumatol; 2023 Apr; 41(4):928-935. PubMed ID: 36912339
[TBL] [Abstract][Full Text] [Related]
33. Comparative Effectiveness of Rituximab- Versus Cyclophosphamide-Based Remission Induction Strategies in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis for the Risk of Kidney Failure and Mortality.
Wallace ZS; Fu X; Cook C; Ahola C; Williams Z; Doliner B; Hanberg JS; Stone JH; Zhang Y; Choi HK
Arthritis Rheumatol; 2023 Sep; 75(9):1599-1607. PubMed ID: 37011036
[TBL] [Abstract][Full Text] [Related]
34. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2).
Charles P; Terrier B; Perrodeau É; Cohen P; Faguer S; Huart A; Hamidou M; Agard C; Bonnotte B; Samson M; Karras A; Jourde-Chiche N; Lifermann F; Gobert P; Hanrotel-Saliou C; Godmer P; Martin-Silva N; Pugnet G; Matignon M; Aumaitre O; Viallard JF; Maurier F; Meaux-Ruault N; Rivière S; Sibilia J; Puéchal X; Ravaud P; Mouthon L; Guillevin L;
Ann Rheum Dis; 2018 Aug; 77(8):1143-1149. PubMed ID: 29695500
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of remission-induction regimens for ANCA-associated vasculitis.
Specks U; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Fessler BJ; Ding L; Viviano L; Tchao NK; Phippard DJ; Asare AL; Lim N; Ikle D; Jepson B; Brunetta P; Allen NB; Fervenza FC; Geetha D; Keogh K; Kissin EY; Monach PA; Peikert T; Stegeman C; Ytterberg SR; Mueller M; Sejismundo LP; Mieras K; Stone JH;
N Engl J Med; 2013 Aug; 369(5):417-27. PubMed ID: 23902481
[TBL] [Abstract][Full Text] [Related]
36. The Pharmacogenomic Association of Fcγ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Cartin-Ceba R; Indrakanti D; Specks U; Stone JH; Hoffman GS; Kallenberg CG; Langford CA; Merkel PA; Spiera RF; Monach PA; St Clair EW; Seo P; Tchao NK; Ytterberg SR; Brunetta PG; Song H; Birmingham D; Rovin BH;
Arthritis Rheumatol; 2017 Jan; 69(1):169-175. PubMed ID: 27482943
[TBL] [Abstract][Full Text] [Related]
37. The management of anti-neutrophil cytoplasmic antibody-associated vasculitis: what has changed in the last 10 years?
Suresh E
Br J Hosp Med (Lond); 2022 Feb; 83(2):1-10. PubMed ID: 35243884
[TBL] [Abstract][Full Text] [Related]
38. ANCA-Associated Vasculitis: Core Curriculum 2020.
Geetha D; Jefferson JA
Am J Kidney Dis; 2020 Jan; 75(1):124-137. PubMed ID: 31358311
[TBL] [Abstract][Full Text] [Related]
39. Targeted immunotherapy strategies in ANCA-associated vasculitis.
Puéchal X
Joint Bone Spine; 2019 May; 86(3):321-326. PubMed ID: 30201478
[TBL] [Abstract][Full Text] [Related]
40. Asthma control in eosinophilic granulomatosis with polyangiitis treated with rituximab.
Casal Moura M; Berti A; Keogh KA; Volcheck GW; Specks U; Baqir M
Clin Rheumatol; 2020 May; 39(5):1581-1590. PubMed ID: 31897956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
